Investors may be wondering if Agios Pharmaceuticals, at around US$27 per share, is offering fair value or an entry point that ...

CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced the ...

Agios Pharmaceuticals will sell its rights to the 15% royalty it holds on potential U.S. net sales of vorasidenib to Royalty Pharma. Royalty Pharma announced this week that it will pay Agios $905 ...

The average one-year price target for Agios Pharmaceuticals (NasdaqGS:AGIO) has been revised to $39.20 / share. This is an increase of 19.62% from the prior estimate of $32.77 dated December 18, 2025.

We came across a bullish thesis on Agios Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AGIO. Agios Pharmaceuticals, Inc.’s share was ...

After Agios' big pivot away from oncology back in 2020 and its first-in-class drug approval earlier this year, the drugmaker is gearing up for more changes. In a move unveiled Tuesday afternoon, Agios ...

Agios Pharmaceuticals Inc. has agreed to sell its oncology business to Boston’s Servier Pharmaceuticals in a deal worth up to $2 billion. Agios, of Cambridge, which has two cancer drugs on the market ...

Cambridge, Massachusetts-based Agios will market its new product, a twice-daily tablet, under the name “Pyrukynd.” The FDA’s Thursday approval covers use of the drug in adults who have an inherited ...

Agios Pharmaceuticals has announced that the European Commission has granted orphan medicinal product designation to mitapivat, an oral small molecule pyruvate kinase (PK) activator, for the treatment ...

On Thursday, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are not regularly transfused ...

Like all avid fly fishermen, I can recount many stories about the big ones that got away. The same goes for my experience in venture capital, as I’ve certainly missed some big ones. With the ...